A phase I/II clinical trial (NCT01583686) using anti-MSLN CAR-T cells in patients with metastatic solid tumors, including ovarian cancer, after pre-treatment with cyclophosphamide and fludarabine was terminated due to insufficient accrual after 6 years. The gene discussed is MSLN; the disease is ovarian carcinoma.